Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00782379 · OUTCOME

Disease Free Survival at 12 Months

Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer · Source last updated 2013-11-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
12 months

What was measured

Disease free survival refers to patients with no evidence of disease after transplant, at the 12 month time point.

Analysis population: 14 patients were alive at one year and therefore were eligible to be evaluated for disease free survival at 1 year

Groups in this outcome

Haploidentical Transplant

Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Haploidentical Transplant14

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Haploidentical Transplant7Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        7
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    units
    Participants
description
Disease free survival refers to patients with no evidence of disease after transplant, at the 12 month time point.
groups
  1. description
    Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant
    id
    OG000
    title
    Haploidentical Transplant
param Type
NUMBER
population Description
14 patients were alive at one year and therefore were eligible to be evaluated for disease free survival at 1 year
reporting Status
POSTED
time Frame
12 months
title
Disease Free Survival at 12 Months
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice